BioAge Labs aims to raise $180M from IPO, private placement to fund obesity trials

BioAge Labs is eyeing around $180 million in initial proceeds from an IPO and a private placement, funds the metabolic-focused biotech will use to push its lead obesity prospect through the clinic.